An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer

References

• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug;31(8):1056–1064.
   PubMed Web of Science ®Google Scholar
• Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018 Feb 19;17(1):52.
   PubMedGoogle Scholar
• Tamura T, Kiura K, Seto T, et al. Three-year follow-up of an alectinib Phase I/II study in ALK-Positive non-small-cell lung cancer: AF-001JP. J Clin Oncol. 2017 May 10;35(14):1515–1521.
   PubMed Web of Science ®Google Scholar
• Thai AA, Solomon BJ. Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer? Ann Oncol. 2018 Nov 1;29(11):2160–2162.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: cNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29(11):2214–2222. doi: 10.1093/annonc/mdy405
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-Rearranged non-small-cell lung cancer: a Phase II global study. J Clin Oncol. 2016 Mar 1;34(7):661–668.
   PubMed Web of Science ®Google Scholar
• Paik J, Dhillon S. Alectinib: a review in advanced, ALK-Positive NSCLC. Drugs. 2018 Aug; 78(12):1247–1257. doi: 10.1007/s40265-018-0952-0
   PubMed Web of Science ®Google Scholar
• Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci. 2020 Dec;111(12):4540–4547.
   PubMed Web of Science ®Google Scholar
• Prokoph N, Larose H, Lim MS, et al. Treatment options for paediatric anaplastic large cell lymphoma (alcl): current standard and beyond. Cancers (Basel). 2018 Mar 30;10(4):99.
   PubMed Web of Science ®Google Scholar
• Kawauchi D, Takahashi M, Satomi K, et al. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. Cancer Sci. 2021 Jun;112(6):2442–2453.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Fernandez Bruno M, Bracht JWP, et al. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. Onco Targets Ther. 2019;12:4567–4575. doi: 10.2147/OTT.S174548
   PubMed Web of Science ®Google Scholar
• Hui B, Zhang J, Shi X, et al. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer. Jpn J Clin Oncol. 2020 Dec 16;50(12):1470–1474.
   PubMed Web of Science ®Google Scholar
• Urbanska EM, Santoni-Rugiu E, Melchior LC, et al. Intracranial response of ALK(+) non-small-cell lung cancer to second-line dose-escalated brigatinib after alectinib discontinuation due to drug-induced hepatitis and relapse after whole brain radiotherapy followed by stereotactic radiosurgery. Clin Lung Cancer. 2021 Jul;22(4):e528–e532.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Kobayashi T, Asoh K, et al. 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J Med Chem. 2011 Sep 22;54(18):6286–6294.
   PubMed Web of Science ®Google Scholar
• Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 2015 Jan; 5(1):34–37. doi: 10.1016/j.apsb.2014.12.007
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679–690.
   PubMed Web of Science ®Google Scholar
• Hirota T, Muraki S, Ieiri I. Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet. 2019 Apr;58(4):403–420. doi: 10.1007/s40262-018-0689-7
   PubMed Web of Science ®Google Scholar
• Harvey RD, Mileham KF, Bhatnagar V, et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of cancer research washout period and concomitant medication work group. Clin Cancer Res. 2021 May 1;27(9):2400–2407.
   PubMed Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023–1028.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014 Sep;15(10):1119–1128.
   PubMed Web of Science ®Google Scholar
• Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2018 Jul;121:37–40.
   PubMed Web of Science ®Google Scholar
• Liu SN, Agarwal P, Heinig K, et al. Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling. Clin Transl Sci. 2023 Mar 28. doi: 10.1111/cts.13515
   Web of Science ®Google Scholar
• Ishiura Y, Nomura S, Ishii Y, et al. Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules. J Oncol Pharm Pract. 2023 Feb;5:10781552231155374.
   Google Scholar
• Yu H, Sun S, Hu X, et al. Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. Onco Targets Ther. 2019;12:6481–6495. doi: 10.2147/OTT.S185115
   PubMed Web of Science ®Google Scholar
• Yang JC, Ou SI, De Petris L, et al. Pooled systemic efficacy and safety data from the pivotal Phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol. 2017 Oct;12(10):1552–1560.
   PubMed Web of Science ®Google Scholar
• Noe J, Lovejoy A, Ou SI, et al. ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-Positive NSCLC: pooled analysis of two prospective trials. J Thorac Oncol. 2020 Apr;15(4):601–608.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-Positive non-small-cell lung cancer. J Clin Oncol. 2016 Dec;34(34):4079–4085.
   PubMed Web of Science ®Google Scholar
• Perol M, Pavlakis N, Levchenko E, et al. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Dec;138:79–87.
   PubMed Web of Science ®Google Scholar
• Liang F. Unstable estimation of investigator-assessed median progression-free survival in the updated report of ALEX trial. J Thorac Oncol. 2019 Sep; 14(9):e195–e196. doi: 10.1016/j.jtho.2019.04.011
   PubMed Web of Science ®Google Scholar
• Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437–446.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhang X, He S, et al. Crizotinib versus alectinib for the treatment of ALK-positive non-small cell lung cancer: a systematic review and meta-analysis. Chemotherapy. 2022;67(2):67–80. doi: 10.1159/000521452
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 Jan;139:195–199.
   PubMed Web of Science ®Google Scholar
• Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018 Jun 1;29(6):1409–1416.
   PubMed Web of Science ®Google Scholar
• Hutchinson L. Targeted therapies: j-ALEX hints at new first-line in NSCLC. Nat Rev Clin Oncol. 2017 Jul; 14(7):394. doi: 10.1038/nrclinonc.2017.80
   PubMed Web of Science ®Google Scholar
• Hotta K, Hida T, Nokihara H, et al. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open. 2022 Aug;7(4):100527.
   PubMedGoogle Scholar
• Morcos PN, Bogman K, Hubeaux S, et al. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 2017 Mar;79(3):559–568.
   PubMed Web of Science ®Google Scholar
• Cirne F, Zhou S, Kappel C, et al. ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis. Lung Cancer. 2021 Nov;161:9–17.
   PubMed Web of Science ®Google Scholar
• Pruis MA, Veerman GDM, Hassing HC, et al. Cardiac toxicity of alectinib in patients with ALK+ lung cancer: outcomes of cardio-oncology follow-up. JACC Cardio Oncol. 2023 Feb;5(1):102–113.
   PubMedGoogle Scholar
• Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: aSCEND-9. Cancer Sci. 2018 Sep;109(9):2863–2872.
   PubMed Web of Science ®Google Scholar
• Kaneda H, Kizaki M, Ochi M, et al. Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study. Sci Rep. 2020 Oct 8;10(1):16773.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Crino L, Felip E, et al. The accelerated path of ceritinib: translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr;55:181–189.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-Positive non-small-cell lung cancer. N Engl J Med. 2017 Aug 31;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29–39.
   PubMed Web of Science ®Google Scholar
• Peng L, Xiao K, Cui J, et al. Successful treatment with ensartinib after alectinib-induced hyperbilirubinemia in ALK-Positive NSCLC. Onco Targets Ther. 2021;14:3409–3415. doi: 10.2147/OTT.S310756
   PubMed Web of Science ®Google Scholar
• Shalata W, Massalha I, Agbarya A. Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature. Anticancer Drugs. 2021 Apr 1;32(4):456–459.
   PubMed Web of Science ®Google Scholar
• Cleary Y, Gertz M, Morcos PN, et al. Model-based assessments of CYP-mediated drug-drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development. Clin Pharmacol Ther. 2018 Sep;104(3):505–514.
   PubMed Web of Science ®Google Scholar
• Ou SI, Gadgeel SM, Barlesi F, et al. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 Jan;139:22–27.
   PubMed Web of Science ®Google Scholar
• Okuma Y, Tanaka Y, Kamei T, et al. Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer. Onco Targets Ther. 2015;8:1321–1325. doi: 10.2147/OTT.S83179
   PubMed Web of Science ®Google Scholar
• Farooq S, Narala S, Pacha O. Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome. JAAD Case Rep. 2020 Dec; 6(12):1339–1341. doi: 10.1016/j.jdcr.2020.09.007
   PubMedGoogle Scholar
• Seegobin K, Majeed U, Lou Y, et al. Patients with high-grade alectinib-induced skin rash: how do we desensitize these patients? A case report and review of literature. SAGE Open Med Case Rep. 2020;8:2050313X20966895.
   PubMed Web of Science ®Google Scholar
• Shirasawa M, Kubotaa M, Harada S, et al. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report. Lung Cancer. 2016 Sep;99:66–68.
   PubMed Web of Science ®Google Scholar
• Kimura T, Sowa-Osako J, Nakai T, et al. Alectinib-induced erythema multiforme and successful rechallenge with alectinib in a patient with anaplastic lymphoma kinase-rearranged lung cancer. Case Rep Oncol. 2016 Sep;9(3):826–832.
   PubMedGoogle Scholar
• Anderson BE, Luczak TS, Ries LM, et al. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash. J Oncol Pharm Pract. 2020 Dec;26(8):2028–2030.
   PubMed Web of Science ®Google Scholar
• Myall NJ, Lei AQ, Wakelee HA. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. Transl Lung Cancer Res. 2021 Jan; 10(1):487–495. doi: 10.21037/tlcr-20-564
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Okamoto I, Otsubo K, et al. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. Invest New Drugs. 2015 Oct;33(5):1148–1150.
   PubMed Web of Science ®Google Scholar
• Huang JR, Chou CW, Chao HS. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. J Oncol Pharm Pract. 2021 Jul; 27(5):1311–1314. doi: 10.1177/1078155220961557
   PubMed Web of Science ®Google Scholar
• Kaira K, Naruse I, Shimizu K, et al. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib. J Cancer Res Ther. 2020 Jul;16(4):919–921.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yoshioka H, Arita M, et al. Interstitial lung disease induced by alectinib (CH5424802/RO5424802). Jpn J Clin Oncol. 2015 Feb;45(2):221–224.
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Sagara H. Alectinib-Induced Diffuse Alveolar Hemorrhage. Arch Bronconeumol. 2023 Mar 21;59(6):396.
   PubMed Web of Science ®Google Scholar
• Ulhoi MP, Sorensen BS, Meldgaard P. Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. Case Rep Oncol. 2021 Sep; 14(3):1323–1327. doi: 10.1159/000518081
   PubMed Web of Science ®Google Scholar
• Lee CS, Sullivan K. Alectinib-induced hemolytic anemia. J Oncol Pharm Pract. 2023 Jan;5:10781552221147840. doi: 10.1177/10781552221147840
   Google Scholar
• El Sayed R, Tehfe M, Blais N. Successful treatment with brigatinib after alectinib-induced hemolytic anemia in patients with metastatic lung adenocarcinoma-a case series. Curr Oncol. 2022 Dec 30;30(1):518–528.
   PubMed Web of Science ®Google Scholar
• Misawa K, Nakamichi S, Iida H, et al. Alectinib-induced severe hemolytic anemia in a patient with ALK-Positive non-small cell lung cancer: a case report. Onco Targets Ther. 2023;16:65–69. doi: 10.2147/OTT.S398375
   PubMed Web of Science ®Google Scholar
• Kostova EB, Beuger BM, Klei TR, et al. Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Biosci Rep. 2015 Apr 16;35(2). doi: 10.1042/BSR20150019
   PubMedGoogle Scholar
• Guihard S, Clay D, Cocault L, et al. The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis. Blood. 2010 May 6;115(18):3686–3694.
   PubMed Web of Science ®Google Scholar
• An XL, Takakuwa Y, Nunomura W, et al. Modulation of band 3-ankyrin interaction by protein 4.1. Functional implications in regulation of erythrocyte membrane mechanical properties. J Biol Chem. 1996 Dec 27;271(52):33187–33191.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Hernandez MA, de la Cruz-Ojeda P, Lopez-Grueso MJ, et al. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020 Sep;36:101510.
   PubMed Web of Science ®Google Scholar
• Sisi M, Fusaroli M, De Giglio A, et al. Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Target Oncol. 2022 Jan;17(1):43–51.
   PubMed Web of Science ®Google Scholar
• He D, Lasek AW. Anaplastic lymphoma kinase regulates internalization of the dopamine D2 receptor. Mol Pharmacol. 2020 Feb; 97(2): 123–131. doi: 10.1124/mol.119.117473
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Morcus R, Tahir M, et al. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature. J Med Case Rep. 2018 Oct 19;12(1):303.
   PubMedGoogle Scholar
• Prado-Mel E, Ciudad-Gutierrez P, Sanchez-Martin A, et al. Alectinib - induced acute renal failure. J Oncol Pharm Pract. 2023 Apr 6:10781552231167808. doi: 10.1177/10781552231167808
   Web of Science ®Google Scholar
• Nagai K, Ono H, Matsuura M, et al. Progressive renal insufficiency related to ALK inhibitor, alectinib. Oxf Med Case Rep. 2018 Apr;2018(4):omy009.
   PubMedGoogle Scholar
• Bonilla M, Jhaveri KD, Izzedine H. Anaplastic lymphoma kinase inhibitors and their effect on the kidney. Clin Kidney J. 2022 Aug; 15(8): 1475–1482. doi: 10.1093/ckj/sfac062
   PubMed Web of Science ®Google Scholar
• Scarfone G, Fumagalli M, Imbimbo M, et al. First case report of pregnancy on alectinib in a woman with metastatic ALK-Rearranged lung cancer: a case report. J Thorac Oncol. 2021 May;16(5):873–877.
   PubMed Web of Science ®Google Scholar
• Shang M, Luo X, Wu J, et al. The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout pregnancy: a case report. Lung Cancer. 2023 Jun;180:107188. doi: 10.1016/j.lungcan.2023.107188
   PubMed Web of Science ®Google Scholar
• Hsu JC, Jaminion F, Guerini E, et al. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1357–1370.
   PubMedGoogle Scholar
• Morcos PN, Cleary Y, Guerini E, et al. Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev. 2017 May;6(3):280–291.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Nagao S, Takanashi K, et al. Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib. Xenobiotica. 2017 Dec;47(12):1042–1051. doi: 10.1080/00498254.2016.1261308
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Yanagitani N, Seto T, et al. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). Transl Lung Cancer Res. 2021 Jan;10(1):314–325.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Furugaki K, Harada N, et al. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. Cancer Biol Ther. 2020 Sep 1;21(9):863–870.
   PubMed Web of Science ®Google Scholar
• Valenciaga A, Saji M, Yu L, et al. Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.122225
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang R, Lin Z, et al. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38alpha/MYC/PD-L1 signaling in non-small cell lung cancer. J Hematol Oncol. 2020 Jul 20;13(1):99.
   PubMed Web of Science ®Google Scholar
• Jazieh KA, Budd GT, Dalpiaz N, et al. Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 2019 Nov;19(11):917–919.
   PubMed Web of Science ®Google Scholar
• Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021 Feb;186(1):219–227.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma Z, Sun X, et al. Interstitial lung disease in patients treated with cyclin-dependent kinase 4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast. 2022 Apr;62:162–169.
   PubMed Web of Science ®Google Scholar
• Cazzaniga ME, Danesi R, Girmenia C, et al. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Treat. 2019 Aug;176(3):483–494.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020 Jan;48:100663.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018 Aug 7;17(1):115.
   PubMedGoogle Scholar
• Muenchow A, Weller S, Hinterleitner C, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis. 2020 Aug 24;11(8):701.
   PubMed Web of Science ®Google Scholar
• Gong X, Tian M, Cao N, et al. Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation. J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI147031
   Web of Science ®Google Scholar
• Albert MC, Brinkmann K, Pokrzywa W, et al. CHIP ubiquitylates NOXA and induces its lysosomal degradation in response to DNA damage. Cell Death Dis. 2020 Sep 10;11(9):740.
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome inhibition overcomes ALK-TKI resistance in ALK-Rearranged/TP53-mutant NSCLC via noxa expression. Clin Cancer Res. 2021 Mar 1;27(5):1410–1420.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ozasa H, Aoki W, et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat Commun. 2020 Jan 3;11(1):74.
   PubMed Web of Science ®Google Scholar
• Jin H, Lian N, Bian M, et al. Oroxylin a inhibits ethanol-induced hepatocyte senescence via YAP pathway. Cell Prolif. 2018 Jun;51(3):e12431.
   PubMed Web of Science ®Google Scholar
• Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-Mutated NSCLC: dusk or dawn? J Thorac Oncol. 2021 Aug;16(8):1267–1288.
   PubMed Web of Science ®Google Scholar
• Lurienne L, Cervesi J, Duhalde L, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol. 2020 Jul;15(7):1147–1159.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 May 26;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Smit EF, de Langen AJ. Pembrolizumab for all PD-L1-positive NSCLC. Lancet. 2019 May 4;393(10183):1776–1778.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537–546.
   PubMed Web of Science ®Google Scholar
• Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344–1357.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020 Oct 1;383(14):1328–1339.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Chin E, Yeap BY, et al. Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer. J Thorac Oncol. 2019 Jan;14(1):135–140.
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Garcia-Roman S, Molina-Vila MA, et al. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. Transl Oncol. 2021 Jan;14(1):100887.
   PubMed Web of Science ®Google Scholar
• Gilbert JA. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC. Lancet Oncol. 2017 Jul; 18(7):e377. doi: 10.1016/S1470-2045(17)30482-5
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 Jul 1;390(10089):3–4.
   PubMed Web of Science ®Google Scholar
• Alectinib approved for ALK+ lung cancer. Cancer Discov. 2016 Feb;6(2):115. doi: 10.1158/2159-8290.CD-NB2016-001
   Web of Science ®Google Scholar
• Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb;10(2):232–236.
   PubMed Web of Science ®Google Scholar
• Kong X, Pan P, Sun H, et al. Drug discovery targeting anaplastic lymphoma kinase (ALK). J Med Chem. 2019 Dec 26;62(24):10927–10954.
   PubMed Web of Science ®Google Scholar
• Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019 Dec;81:101911.
   PubMed Web of Science ®Google Scholar
• Yang K, Chen Y, To KK, et al. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2017 Mar 17;49(3):e303.
   PubMedGoogle Scholar
• Zhu V, Ou SH. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 2017 Apr; 16(4):509–514. doi: 10.1080/14740338.2017.1299706
   PubMed Web of Science ®Google Scholar
• Vavala T, Novello S. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Ther Adv Med Oncol. 2018;10:1758835918789364. doi: 10.1177/1758835918789364
   Web of Science ®Google Scholar